More News

06 Jun 2017 CRISPR Therapeutics and MaSTherCell SA sign service agreement for the development and manufacturing of allogeneic cell therapies
06 Jun 2017 Intellia Therapeutics and San Raffaele University and Research Hospital to Combine CRISPR/Cas9 Genome Editing with Enhanced Cell Therapies to Fight Cancer
06 Jun 2017 Lundbeck obtains rights to breakthrough research in Alzheimer’s disease
06 Jun 2017 Novartis announces clinical collaboration with Bristol-Myers Squibb to evaluate potential treatments in metastatic colorectal cancer
05 Jun 2017 Fortress Biotech Announces that its Subsidiary, Mustang Bio, Enters into License Agreements with City of Hope for Novel CAR T Immunotherapies
04 Jun 2017 Sevion Therapeutics Inc. and Eloxx Pharmaceuticals Ltd Announce the Entering into of an Acquisition Transaction
04 Jun 2017 Merck Strengthens Immuno-Oncology Portfolio through Expansion of F-star Collaboration including LAG-3/PD-L1 Bispecific Antibody
04 Jun 2017 Innate Pharma strengthens its proprietary pipeline with the acquisition of anti-C5aR, a first-in-class clinical-stage antibody, from Novo Nordisk A/S
04 Jun 2017 Bristol-Myers Squibb and Seattle Genetics Expand Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) and ADCETRIS® (Brentuximab Vedotin) in Pivotal Phase 3 Clinical Trial in Relapsed Hodgkin Lymphoma
02 Jun 2017 OBI Pharma Announces Acquisition of TH-3424 from Threshold Pharmaceuticals
31 May 2017 Inspyr Therapeutics and Lewis and Clark Pharmaceuticals to Merge
31 May 2017 Array BioPharma And Ono Pharmaceutical Co., Ltd. Announce A License, Development And Commercialization Partnership For Two Novel Oncology Compounds, Binimetinib And Encorafenib
31 May 2017 MabVax Therapeutics Signs Research Agreement with Memorial Sloan Kettering Cancer Center to Develop Novel CAR T-Cell Based Anti-Cancer Immunotherapies for Treatment of Pancreatic and Small Cell Lung Cancers
31 May 2017 EpimAb Biotherapeutics Collaborates with WuXi Biologics to Advance Lead Bispecific Antibody Candidate towards Clinical Development
31 May 2017 Vetter and Microdermics Enter into a Strategic Cooperation Agreement to Develop Innovative Microneedle Drug Delivery Systems
31 May 2017 IMIDomics SL and Celgene Corporation Enter into Strategic Collaboration to Advance the Development of Novel Treatments for Patients with Immune-Mediated Inflammatory Diseases
30 May 2017 Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
30 May 2017 Arcturus Therapeutics to Receive Up to $3 Million from Cystic Fibrosis Foundation Therapeutics to Advance a Novel LUNAR-Formulated mRNA CFTR Therapeutic
30 May 2017 Janssen Enters Into Worldwide Exclusive License and Collaboration Agreement With Protagonist Therapeutics, Inc. for Oral Interleukin-23 Receptor Antagonist Drug Candidate for the Treatment of Inflammatory Bowel Disease
30 May 2017 ImmunoGen and Sanofi Amend License Agreements
30 May 2017 Lonza Acquires Cell and Gene Contract Manufacturer PharmaCell
26 May 2017 Merck Enters Exclusive Worldwide License Agreement with Teijin Pharma for Investigational Antibody Candidate Targeting Tau
24 May 2017 Pierre Fabre Pharmaceuticals Acquires Promising Assets from Igenica Biotherapeutics in the Field of Immuno-Oncology
24 May 2017 Bioverativ to Acquire Clinical-Stage Rare Disease Biotechnology Company, True North Therapeutics
24 May 2017 Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset from ImmunoGen

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing